4.7 Article

Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia

Related references

Note: Only part of the references are listed.
Article Hematology

Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia

Daniel R. Richardson et al.

Summary: The ASXL1 and SRSF2 mutations in AML are frequently associated with poor outcomes, especially in patients with preexisting myeloid malignancies. Patients with co-mutations of ASXL1 and SRSF2 have a higher probability of death compared to those with single mutations, with a trend towards inferior overall survival, largely attributable to a high proportion of secondary-AML patients in this cohort.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Article Oncology

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

Richard A. Larson et al.

Summary: The addition of midostaurin to standard chemotherapy in FLT3-mutant AML patients has shown significant benefits in reducing the risk of death and relapse. However, the impact of maintenance therapy on overall outcomes remains inconclusive.

LEUKEMIA (2021)

Article Hematology

Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations

Lili Zhou et al.

Summary: The study found that ASXL1 mutation is a poor prognostic factor in AML patients, while allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve the survival rate of AML patients with ASXL1 mutations.

HEMATOLOGY (2021)

Review Oncology

A precision medicine approach to management of acute myeloid leukemia in older adults

Shristi Upadhyay Banskota et al.

CURRENT OPINION IN ONCOLOGY (2020)

Article Multidisciplinary Sciences

The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia

Dimitrios Papaioannou et al.

NATURE COMMUNICATIONS (2019)

Article Medicine, General & Internal

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

R. M. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Biochemistry & Molecular Biology

De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome

Anshika Srivastava et al.

HUMAN MOLECULAR GENETICS (2016)

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Correction Biochemistry & Molecular Biology

ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1 (vol 285, pg 18, 2010)

Sang-Wang Lee et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

Article Hematology

Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse

Costa Bachas et al.

BRITISH JOURNAL OF HAEMATOLOGY (2014)

Review Oncology

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

Veronique Gelsi-Boyer et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)

Article Medicine, General & Internal

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Jay P. Patel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Letter Oncology

Mutations of ASXL1 gene in myeloproliferative neoplasms

N. Carbuccia et al.

LEUKEMIA (2009)

Article Biochemistry & Molecular Biology

Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor

Yang-Sook Cho et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)